Non-benzodiazepine pharmacotherapy of anxiety and panic in substance abusing patients

Psychiatric Annals

Volumn 28, Issue 3, 1998, Pages 142-153

  Longo, Lance P ^a,b,c  

^a AURORA SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032378998     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19980301-10     Document Type: Article

References (148)

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;254:2511-2518.
2. Weissman MM. Anxiety and alcoholism. J Clin Psychiatry. 1988;49(Suppl 10):17-19.
3. Brady KT, Lydiard RB. The association of alcoholism and anxiety. Psychiatric_Quarterly. 1993;64:135-149.
4. Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. Am J Psychiatry. 1990;147:685-695.
5. Linnoila MI. Anxiety and alcoholism. J Clin Psychiatry. 1989;50(Suppl 11):26-29.
6. Schuckit MA, Hasselbrock V. Alcohol dependence and anxiety disorders: What is the relationship? Am J Psychiatry. 1994;151:1723-1734.
7. Cloninger CR. Neurogenetic adaptive mechanisms in alcoholism. Science. 1987;236:410-416.
8. Schuckit MA. Low level of response to alcohol as a predictor of future alcoholism. Am J Psychiatry. 1994; 151:184-189.
9. Ciraulo DA, Srid-Segal O, Knapp, C, et al. Liability to alprazolam abuse in daughters of alcoholics. Am J Psychiatry. 1996;153:956-958.
10. Miller NS, Gold MS, Stennie K Benzodiazepines: the dissociation of addiction from pharmacological dependence/withdrawal. Psychiatric Annals. 1995;25:149-152
11. Dupont RL. Anxiety and addiction: A clinical perspective on comorbity. Bulletin of the Menninger Clinic. 1995;59 (Suppl A):A53-A72.
12. Salzman C. The APA task force report on benzodiaepine dependence, toxicity, and abuse. Am J Psychiatry. 191;148:151-152.
13. Busto U, Romach MK, Sellers EM. Multiple drug use and psychiatric comorbidity in patients admitted to the hospital with severe benzodiazepine dependence. J Clin Psychopharm. 1996;16:51-57.
14. Ashton H. Toxicity and adverse consequences of benzodiazepine use. Psychiatric Annals. 1995;25(3):159.
15. Janicak PG, Davis JM, Preskhorn SH, Ayd FJ. In: Principles and Practice of Psychopharmacotherapy. Baltimore: Williams and Wilkins. 1993:287.
16. Greene DS, Dockens RC, Salazar DE, et al. Coadministration of Nefazadone and benzodiazepines, I: pharmacokinetic assessment (abstract). Clin Pharmacol Ther. 1994;55:141
17. Lader M. Long-term benzodiazepine use and psychological functioning. In: Freeman H, Rue Y, eds. The Benzodiazepines in Current Clinical Practice. Royal Society of Medicine Services. International Congress and Symposium Series 1987;114:55-69.
18. Curran V. Memory functions, alertness, and mood of long-term benzodiazepine users: a preliminary investigation of the effects of normal daily dose. J. Psychopharmacology, 1992;6:69-75.
19. Dietch JT, Jennings RK. Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry. 1988;49:184-188.
20. Van Der Bijl P, Roelofse JA. Disinhibitory reactions to benzodiazepines: a review. J Oral Maxillofac Surg. 1991; 49:519-523.
21. Gardas G. Disinhibition of behavior by antianxiety drugs. Psychosomatics. 1980;21:1025-1026.
22. Smith BD, Salzman C. Do benzodiazepines cause depression? Hospital and Community Psychiatry. 1991;42:11:1101-1102.
23. Bergman U, Rosa FW, Baum C, Wiholm B-E, Faich GA. Effects of exposure to benzodiazepines during fetal life. Lancet. 1992;340:694-697.
24. Kales A, Scharf MB, Kales JD. Rebound insomnia: a new clinical syndrome. Insomnia. 1998;201:1039-1041.
25. Mellinger GD, Balter MB, Uhlenhuth EH. Prevalence and correlates of the long-term use of anxiolytics. JAMA. 1984;251:375-379.
26. Marriot S, Tyrer P. Benzodiazepine dependence: avoidance and withdrawal. Drug Safety. 1993;9:93-103.
27. Little HJ, Nutt DJ, Taylor SC. Bi-directional effects of chronic treatment with agonists and inverse agonists at the benzodiazepine receptor, complex. Brain Research Review. 1987;19:371.
28. Salzman C (Ed.) Benzodiazepine dependence, toxicity, and abuse. A task force report of the American Psychiatric Association. APA, Washington, DC. 1990.
29. Busto U, Sellars EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long term therapeutic use of benzodiazepines. N Engl J Med. 1986;315:854-859.
30. Ashton H. Protracted withdrawal syndromes form benzodiazepines. J Subst Abuse Treat. 1991;8:19-28.
31. Busto U, Sellars EM, Naranjo CA, et al. Patterns of benzodiazepine abuse and dependence. Br J Addict. 1986;81:87-94.
32. Dupont RL. Abuse of benzodiazepines - the problems and the solutions. Am J Drug Alcohol Abuse. 1988;145:1-69.
33. Perera KMH, Tulley M, Jenner FA. The use of benzodiazepines among drug addicts. Br J Addict. 1987;82:511-515.
34. Iguchi MY, Griffiths RR, Bickel WK, et al. Relative abuse liability of benzodiazepines in methadone-maintained populations in three cities. In: Problems of Drug Dependence. Edited by Harris LS. Washington, DC, Department of Health and Human Services; 1989.
35. Ciraulo D, Sands BF, Shader RI. Critical review of liability for benzodiazepine abuse among alcoholics. Am J Psych. 1988;145:1501-1506.
36. Gold MS, Miller NS, Stennie K, Populla-Vardi C. Epidemiology of benzodiazepine use and dependence. Psychiatric Annals. 1995;25:146-148.
37. Cowley DS, Roy-Byrne PP, Hommer DW, et al. Sensitivity to benzodiazepines in sons of alcoholics. Biol Psychiatry. 1991;29:104-112.
38. Cowley DS, Roy-Byrne PP, Gordon C, et al. Response to diazepam in sons of alcoholics. Alcoholism Clin Exp Res. 1992;6:1057-1063.
39. Roache JD, Meisch RA. Findings from self-administration research on the addiction potential of benzodiazepines. Psychiatric Annals. 1995;256:153-157.
40. Schatzberg AF. Fluoxetine in the treatment of comorbid anxiety and depression. J Clin Psychiatry. Monograph 1995;13:2-12.
41. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
42. Wetzler S, Katz MM. Problems with the differentiation of anxiety and depression. J Psychiatry Res. 1989;23:1-12.
43. Clayton PJ. The comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. J Clin Psychiatry. 1990;51(Suppl 11):35-39.
44. Clayton PJ, Grove WM, Coryell W, et al. Follow up and family study of anxious depression. Am J Psychiatry. 1991;148:1512-1517.
45. Fawcett J. Targeting treatment in patients with mixed symptoms of anxiety and depression. J Clin Psychiatry. 1990;51(Suppl 11):40-43.
46. Clancy J, Noyes R Jr, Hoenk PR, et al. Secondary depression in anxiety neurosis. J Nerv Ment Dis. 1978;166:846-850.
47. Schatzberg AF, Samson JA, Rotschild AJ, et al. Depression secondary to anxiety: findings from the McLean Hospital depression research. Psychiatric Clin North Am. 1990;13:633-648.
48. Zajecka JM, Ross JS. Management of comorbid anxiety and depression. J Clin Psychiatry. 1995;56(Suppl 2):10-13.
49. Sargant W. The treatment of anxiety states and atypical depressions by the monoamine oxidase inhibitor drugs. J Neuropsychiatry. 1962;3(Suppl 1):97-103.
50. Sargant W, Dally P. Treatment of anxiety states by antidepressant drugs. Br Med J. 1962;1:6-9.
51. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry. 1962;119:432-438.
52. Nutt D, Glue P. Clinical pharmacology of anxiolytics and antidepressants: a psychopharmacological perspective. In: File SE ed. Psychopharmacology of Anxiolytics and Antidepressants. New York: Peragom Press, Inc; 1981:1-28.
53. Rifkin A, Klein DF, Dillon DJ, and Levitt M. Blockade by imipramine or desipramine of panic induced by sodium lactate. Am J Psychiatry. 1981;138:676-677.
54. Kramer P. Listening to Prozac. New York: Viking Press; 1993.
55. Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U. Response of anxiety and agitation symptoms during nefazodone treatment of major depression J Clin Psychiatry. 1995;56(Suppl 6):37-42.
56. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. Arch Gen Psychiatry. 1993;50:884-895.
57. Liebowitz MR, Gorman JM, et al. Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry. 1988;49:252-258.
58. Gelernter CS, Uhde TW, Limbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia. Arch Gen Psychiatry. 1991;48:938-945.
59. Versiani M, Nardi AE, Mundim FD, et al. Pharmacotherapy of social phobia, a controlled study with moclobemide and phenelzine. Br J Psychiatry. 1992;161:353-360.
60. Black B, Uhde TW, Tanter ME. Fluoxetine for the treatment of social phobia. J Clin Psychopharmacol. 1992; 12:293-295.
61. Van Amerigen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry. 1993;54:27-32.
62. Van Vliet IM, dev Boer JA, Westerburg HGM. Psychopharmacological treatment of social phobia: a double blind placebo controlled study with fluvoxamine. Psychopharmacology. 1994;115:128-134.
63. Van Amerigen M, Mancini C, Streiner DL. Sertraline in social phobia. J Affect Disord. 1994;31:141-145.
64. Ringold AL. Paroxetine efficacy in social phobia (letter). J Clin Psychiatry. 1994;55:363-364.
65. Lepold U, Koponow H, Leinonen E. Citalopram in the treatment of social phobia: a report of three cases. Pharmacopsychiatry. 1994;27:181-188.
66. Naranjo CA, Poulos CX, Bremner KE, Lanclot KL. Citalopram decreases desirability, liking and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther. 1992;51:729-739.
67. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res. 1992;16:261-255.
68. Nutt DJ. Pharmacological and behavioral studies of benzodiazepine antagonists and contragonists. In: Benzodiazepine Recognition Site Ligands: Biochemistry and Pharmacology. Biggio G and Costa E (Eds), New York: Raven Press; 1983:153-174.
69. Hafner RJ, Marks I. Exposure in vivo of agoraphobics: contributions of diazepam, group exposure, and anxiety evocation. Psycho Med. 1976;6:71-88.
70. Ashton H. Protracted withdrawal from benzodiazepines: The post-withdrawal syndrome. Psychiatric Annals. 1995;25:174-178.
71. Post RM, Ballenger JC, Uhde TW, et al. Kindling and drug sensitization: Implications for the progressive development of psychopathology and treatment with carbamazepine. In Sandler M (ed): The Psychopharmacology of anticonvulsants. Oxford: Oxford University Press; 1981:27-53.
72. Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry. 1986;47:580-586.
73. Ballenger JC, Burrows GD, Dupont RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988;45:413-422.
74. Pollack MH, Tesar GE, Rosenbaum JF, et al. Clonazepam in the treatment of panic disorder and agoraphobia: a one year follow up. J Clin Psychopharmacol. 1986;6:302-304.
75. Spier SA, Tesar GE, Rosenbaum JF, et al. Treatment of panic disorder and agoraphobia with clonazepam. J Clin Psychiatry. 1986;47:238-242.
76. Rickes K, Schweizer E, et al. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47:899-907.
77. Schweizer E, Rickles K. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psych. 1990;47:908-915.
78. Marks I, O'Sullivan G. Drugs and psychological treatments for agoraphobia/panic and obsessive-compulsive disorders. Br J Psychiatry. 1988;153:650-658.
79. Pollack MH. Long-term management of panic disorder. J Clin Psychiatry. 1990;51(Suppl 5):11-13.
80. Rosenbaum JF, Pollock RA, Jordan SK, Pollack MH. The pharmacotherapy of panic disorder. Bulletin of the Menninger Clinic. 60(Suppl A):54-75.
81. Lydiard RB, Ballenger JC. Antidepressants in panic disorder and agoraphobia. J Affective Dis. 1987;13:153-168.
82. Liebowitz MR. Antidepressants in panic disorders. Br J Psychiatry. 1989;155(Suppl 6):46-52.
83. Noyes R, Garvey MJ, Cook BL, Samuelson L. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow up study. J Clin Psychiatry. 1989;50:163-169.
84. Boyer W. Serotonin uptake inhibitors are superior to imipramine in alleviating panic attacks. Int Acad Biomed Drug Res. 1994;8:55-60.
85. Jobson KO, Davidson JR, Lydiard RB, McCann VD, Pollack MH, Rosenbaum JF. Algorithm for the treatment of panic disorder with agoraphobia. Psychopharmacology Bulletin. 1995;3:483-485.
86. Oehrberg S, Christiansen PE, Behnke K, Borup AI, et al. Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. Br J Psychiatry. 1995;167:374-379.
87. Duboff E, England D, Ferguson JM, Landberg PD, et al. Double-blind comparison of three fixed doses of sertraline and placebo in patients with panic disorder. European Neuropsychopharmacology. 1995;5:287.
88. deBeurs E, Van Balkom A. Lange A, Koele P, Van Dyck R. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological management combined with exposure and of exposure in vivo alone. Am J Psychiatry. 1995;152:683-691.
89. 2 challenge. J Clin Psychiatry. 1996;57:539-542.
90. Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, et al. Fluoxetine in panic disorder. J Clin Psychopharmacology. 1990;10:119-121.
91. Geracioti TD. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry. 1995;20:408-410.
92. Modigh K, Westberg P, Erikson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacology. 1992;12:251-261.
93. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry. 1983;44:8-11.
94. Shore JH, Vollner WM, Tatum EL. Community patterns of post-traumatic stress disorder. J Nerv Ment Dis. 1989;177:681-685.
95. Silver JM, Sandberg DP, Hales RE. New approaches in the pharmacotherapy of post traumatic stress disorder. J Clin Psychiatry. 1990;51(Suppl 10):33-38.
96. Davidson J. Drug therapy of post traumatic stress disorder. Br J Psychiatry. 1992;160:309-314.
97. Pope HG, McElroy SL, Keck PE, Hudson JI. A placebo-controlled study of valproate in mania. Arch Gen Psychiatry. 1991;48:62-68.
98. Mazure CM, Druss BG, Cellar JS. Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol. J Am Geriat Soc. 1992;40:914-916.
99. Wilcox J. Divalproex sodium in the treatment of aggressive behavior. Ann Clin Psychiatry. 1994;6:17-20.
100. Szymanski HV. Divalproex in post traumatic stress disorder. Am J Psychiatry. 1991;148:1086-1087.
101. Woodman CL, Noyes R. Panic disorder: treatment with valproate. J Clin Psychiatry. 1994;55:134-136.
102. Keck PE, Taylor VE, Tugrul KC, et al. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psych. 1993;33:542-546.
103. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry. 1990;35:248-250.
104. Chapman A, Kene PE, Meldrum BS, et al. Mechanism of anticonvulsant action of valproate. Prog Neurobiol. 1982;19:315-359.
105. 3H] dihydropicrotoxinin binding sites at the benzodiazepine-GABA receptor-ionophore complex. Brain Res. 1981;223:218-222.
106. Roy-Byrne PP, Ward NG, Donnelly PJ. Valproate in anxiety and withdrawal syndromes. J Clin Psychiatry. 1989; 50(Suppl 3):44-48.
107. Keck PE Jr, McElroy SL, Friedman LM. Valproate and carbamazepine in the treatment of panic and post traumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol. 1992; 12(Suppl 1):36-41.
108. Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA, Smith JMR. Antiepileptic drugs for the treatment of panic disorder. Neuropsychobiology. 1993;27:150-153.
109. Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry. 1988;145:1104-1109.
110. Goa KL, Ward A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs. 1986;32:114-129.
111. Sussman N. The uses of buspirone in psychiatry. J Clin Psychiatry Monograph. 1994;12:3-19.
112. Peroutka SJ. Selective interaction of novel anxiolytics with 5-hydroxytryptamine 1A receptors. Biological Psychiatry. 1985;20:971-979.
113. Lucki I. Serotonin receptor specificity in anxiety disorders. J Clin Psychiatry. 1996;57(Suppl 6):5-10.
114. Cole JO, Orzack MH, Beake B, et al. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry. 1982;43:69-74.
115. Griffith JD, Jasinski Dr, Caston GP. Investigation of the abuse liability of buspirone in alcohol dependent patients. Am J Med. 1986;80(Suppl):30-35.
116. Tollefson GD, Montague-Clause J, Tollefson SL. Treatment of co-morbid generalized anxiety in a recent detoxified alcoholic population with a selective serotoninergic drug (buspirone). J Clin Psychopharmacol. 1992;12:19-26.
117. Kransler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics. Arch Gen Psychiatry. 1994;51:720-731.
118. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol. 1990;10:675-765.
119. Maruno CA, Hart LL. Buspirone in obsessive-compulsive disorder. Ann Pharmacotherapy. 1992;26:1248-1251.
120. Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry. 1993;150:819-821.
121. Schweitzer E, Rickels K. Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry. 1986;258:204-205.
122. Stein DJ, Hollander E, Liebowitz MR. Neurobiology of impulsivity and the impulse control disorders. Journal of Neuropsychiatry. 1993;5:9-17.
123. Ratey J, Sovner R, Mikkelsen E, et al. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry. 1989;50:382-384.
124. Ratey J, Sovner R, Parks A, et al. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple baseline, placebo lead-in study. J Clin Psychiatry. 1991;52:159-162.
125. Sakanye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. Am J Geriatric Psychiatry. 1993;1:82-84.
126. Levine AM. Buspirone and agitation in head injury. Brain Inj. 1988;2:165-167.
127. Gualtieri CT. Buspirone for the behavior problems of patients with organic brain disorders (letter). J Clin Psychopharmol. 1991;11:280-281.
128. Ratey JJ, Leveroni CL, Miller AC, et al. Low-dose buspirone to treat agitation and maladaptive behavior in brain-injured patients: two case reports (letter). J Clin Psychopharmacol. 1992;12:362-364.
129. Redmond DE. Neurochemical basis for anxiety and anxiety disorders: evidence from drugs which decrease human fear or anxiety. In: Tuma AH and Maser JD eds, Anxiety and the Anxiety Disorders. Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1985:530-555.
130. Redmond DE, Huang Y. Current concepts II: new evidence for a locus coeruleus-norepinephrine connection with anxiety. Life Sci. 1979;15:2149-2162.
131. Charney DS, Henniger GR, Breier A. Noradrenergic function and panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry. 1984;41:751-763.
132. Nutt DJ. Altered alpha-2-adrenoceptor sensitivity in panic disorder. Arch Gen Psychiatry. 1989;46:165-169.
133. George D, Nutt DJ, Walker WV, Porges SW, Adinoff B, Linnoila M. Lactate and hyperventilation substantially attenuate vagal tone in normal volunteers. Arch Gen Psychiatry. 1989;46:153-156.
134. Hayes PE, Schultz SC. Beta-blockers in anxiety disorders. J Affective Disord. 1987;13:119-130.
135. Tyrer P. Anxiolytics not acting at the benzodiazepine receptor: beta blockers. Prog Neuropsychopharmacol Biol Psychiatry. 1992;16:17-26.
136. Salzman C, Miyawaki EK, le Bars P, Kerrihard TN. Neurobiologic basis of anxiety and its treatment. Harvard Rev. Psychiatry. 1993;1:197-206.
137. Gorman JM, Levy GF, Liebowitz MR, McGrath P, et al. Effect of acute beta-adrenergic blockade on lactate-induced panic. Arch Gen Psychiatry. 1983;40:1079-1082.
138. Bond WS. Psychiatric indication for clonidine. The neuropharmacologic and clinical basis. J Clin Psychopharmacol. 1986;6:81-87.
139. Hoehn-Saric R, Merchant AF, Keyser MC, Smith VK. Effects of clonidine on anxiety disorders. Arch Gen Psychiatry. 1981;38:1278-1282.
140. Glue P, Nutt DJ. Clonidine in alcohol withdrawal: a pilot study of differential symptom responses following i.v. clonidine. Alcohol Alcoholism. 1987;22:161-166.
141. Charney DS, Sternberg DE, Kleber HD, Heninger DE, Redmond DE. The clinical use of clonidine in abrupt withdrawal from methadone. Arch Gen Psychiatry. 1981;38:1273-1277.
142. Volavka J, Zito JM, Vitrai J, Czobor P. Clozapine effects on hostility and aggression in schizophrenia (letter). J Clin Psychopharmacol. 1993;13:4:287-289.
143. Ratey JJ, Leveroni C, Kilmer D, Gutheil C, Swartz B. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry. 1993;54:219-223.
144. Gelenberg A, Hopkins H. Antipsychotics in bipolar disorder. J Clin Psychiatry. 1996;5 (Suppl):49-52.
145. Leysen J, Janssen P, Megens A, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994;55(Suppl 5):5-12.
146. McElroy SL, Dessain EC, Pope HG, Cole JO, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 191;52:411-414.
147. Marder SR. Clinical experience with risperidone. J Clin Psychiatry. 1996;57(Suppl 9):57-61.
148. Nutt DJ. Addiction: brain mechanisms and their treatment implications. Lancet. 1996;347:31-36.